Cleveland Clinic and The Hebrew University of Jerusalem will begin a formal initiative to raise funds and develop a virtual global Center for Transformative Nanomedicine. This partnership will harness the power of nanoscience and nanotechnology with the goal of revolutionizing the delivery of new therapies and treatments worldwide.
This major new collaboration will advance research and create a dynamic exchange of knowledge, especially in the areas of cardiovascular disease, neurological disease and cancer, all of which afflict millions worldwide. In partnership, these leading institutions will blaze new paths in the emerging field of nanotechnology, using nanoparticles invisible to the naked eye to create novel drug delivery systems and unique medical technologies with lifesaving potential.
“Our two institutions will leverage resources and begin to combine our scientific knowledge,” says Professor Menahem Ben-Sasson, president, The Hebrew University of Jerusalem. “These powerful interactions will expedite better medical treatments, more rapid, cost-effective diagnostics, and improved healthcare delivery for people the world over.”
Nanotechnology enables doctors to deliver medications to select sites, preventing drugs from degrading in the body before reaching targeted sites because the miniscule particles are protected. This precise technology allows delivery of large doses of drugs to be released at a specific site and only to that site, causing fewer side effects than many traditional treatments. Customized and carefully calibrated drug treatment offers the possibility of greater effectiveness and patient safety. In addition, nanotechnology is used to create inexpensive devices that facilitate therapy and new ways of diagnosing disease. This technology also promises to save money and time. Often, doctors can run tests in their office rather than send samples to a laboratory.
“We are honored to join with Hebrew University to advance the emerging field of nanotechnology,” said Toby Cosgrove, M.D., president and CEO of Cleveland Clinic. “The new Center for Transformative Nanomedicine will ensure development of novel therapeutics to improve longevity, enhance patient well-being, make medical care more cost-effective, and provide dynamic solutions to global health concerns.”
Cleveland Clinic and The Hebrew University of Jerusalem are renowned for propelling innovation in the field of medicine. Cleveland Clinic is a leader nationally and internationally in laboratory-based, translational and clinical research, as well as exceptional patient care. The Hebrew University of Jerusalem is Israel’s top-ranked university and among the top 100 worldwide, achieving success in biotechnology, nanotechnology, molecular modeling and drug development.
The two leading institutions announced a five-year commitment to raising $15 million-plus in first-stage funding to establish the virtual center, which will foster interdisciplinary research at the Hebrew University’s Faculty of Medicine and School of Pharmacy, its Faculty of Science and the Harvey M. Krueger Family Center for Nanoscience and Nanotechnology, in combination with Cleveland Clinic’s Department of Biomedical Engineering, part of Cleveland Clinic’s Lerner Research Institute.
D. Geoffrey Vince, Ph.D., chair of Biomedical Engineering at Cleveland Clinic’s Lerner Research Institute, and Professor Simon Benita, former head of the Institute for Drug Research and the School of Pharmacy at Hebrew University’s Faculty of Medicine, will lead the efforts to develop the global Center for Transformative Nanomedicine.
